338 related articles for article (PubMed ID: 9815812)
21. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation.
Ploug M; Ostergaard S; Hansen LB; Holm A; Danø K
Biochemistry; 1998 Mar; 37(11):3612-22. PubMed ID: 9521680
[TBL] [Abstract][Full Text] [Related]
22. Differential binding of urokinase and peptide antagonists to the urokinase receptor: evidence from characterization of the receptor in four primate species.
Engelholm LH; Behrendt N
Biol Chem; 2001 Mar; 382(3):435-42. PubMed ID: 11347891
[TBL] [Abstract][Full Text] [Related]
23. Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and alpha v beta 5 integrin.
Franco P; Vocca I; Carriero MV; Alfano D; Cito L; Longanesi-Cattani I; Grieco P; Ossowski L; Stoppelli MP
J Cell Sci; 2006 Aug; 119(Pt 16):3424-34. PubMed ID: 16882693
[TBL] [Abstract][Full Text] [Related]
24. Assembly of urokinase receptor-mediated plasminogen activation complexes involves direct, non-active-site interactions between urokinase and plasminogen.
Ellis V; Whawell SA; Werner F; Deadman JJ
Biochemistry; 1999 Jan; 38(2):651-9. PubMed ID: 9888805
[TBL] [Abstract][Full Text] [Related]
25. Urokinase receptor variants in tissue and body fluids.
Høyer-Hansen G; Lund IK
Adv Clin Chem; 2007; 44():65-102. PubMed ID: 17682340
[TBL] [Abstract][Full Text] [Related]
26. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS
Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751
[TBL] [Abstract][Full Text] [Related]
27. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
Zhu F; Jia S; Xing G; Gao L; Zhang L; He F
DNA Cell Biol; 2001 May; 20(5):297-305. PubMed ID: 11410166
[TBL] [Abstract][Full Text] [Related]
28. High-molecular-weight serum protein complexes differentially promote cell migration and the focal adhesion localization of the urokinase receptor in human glioma cells.
Hedberg KK; Stauff C; Høyer-Hansen G; Rønne E; Griffith OH
Exp Cell Res; 2000 May; 257(1):67-81. PubMed ID: 10854055
[TBL] [Abstract][Full Text] [Related]
29. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.
Pedersen N; Schmitt M; Rønne E; Nicoletti MI; Høyer-Hansen G; Conese M; Giavazzi R; Dano K; Kuhn W; Jänicke F
J Clin Invest; 1993 Nov; 92(5):2160-7. PubMed ID: 8227331
[TBL] [Abstract][Full Text] [Related]
30. Structural analysis of the interaction between urokinase-type plasminogen activator and its receptor: a potential target for anti-invasive cancer therapy.
Ploug M; Gårdsvoll H; Jørgensen TJ; Lønborg Hansen L; Danø K
Biochem Soc Trans; 2002 Apr; 30(2):177-83. PubMed ID: 12023847
[TBL] [Abstract][Full Text] [Related]
31. Aspirin inhibits highly invasive prostate cancer cells.
Lloyd FP; Slivova V; Valachovicova T; Sliva D
Int J Oncol; 2003 Nov; 23(5):1277-83. PubMed ID: 14532966
[TBL] [Abstract][Full Text] [Related]
32. Cancer cells release a covalent complex containing disulfide-linked domains from urinary plasminogen activator, neural cell adhesion molecule, and haptoglobin alpha and beta chains.
Harvey SR; Nayak SK; Markus G; Ouhammouch M; Hemperly JJ; Dillman RO; Doyle DJ
Arch Biochem Biophys; 1997 Sep; 345(2):289-98. PubMed ID: 9308901
[TBL] [Abstract][Full Text] [Related]
33. Production of second messengers following chemotactic and mitogenic urokinase-receptor interaction in human fibroblasts and mouse fibroblasts transfected with human urokinase receptor.
Anichini E; Fibbi G; Pucci M; Caldini R; Chevanne M; Del Rosso M
Exp Cell Res; 1994 Aug; 213(2):438-48. PubMed ID: 8050501
[TBL] [Abstract][Full Text] [Related]
34. Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody.
Mohanam S; Sawaya R; McCutcheon I; Ali-Osman F; Boyd D; Rao JS
Cancer Res; 1993 Sep; 53(18):4143-7. PubMed ID: 8395977
[TBL] [Abstract][Full Text] [Related]
35. Human urokinase-type plasminogen activator primes neutrophils for superoxide anion release. Possible roles of complement receptor type 3 and calcium.
Cao D; Mizukami IF; Garni-Wagner BA; Kindzelskii AL; Todd RF; Boxer LA; Petty HR
J Immunol; 1995 Feb; 154(4):1817-29. PubMed ID: 7836767
[TBL] [Abstract][Full Text] [Related]
36. Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue.
Luther T; Magdolen V; Albrecht S; Kasper M; Riemer C; Kessler H; Graeff H; Müller M; Schmitt M
Am J Pathol; 1997 Apr; 150(4):1231-44. PubMed ID: 9094980
[TBL] [Abstract][Full Text] [Related]
37. The Pseudomonas aeruginosa LasB metalloproteinase regulates the human urokinase-type plasminogen activator receptor through domain-specific endoproteolysis.
Leduc D; Beaufort N; de Bentzmann S; Rousselle JC; Namane A; Chignard M; Pidard D
Infect Immun; 2007 Aug; 75(8):3848-58. PubMed ID: 17517866
[TBL] [Abstract][Full Text] [Related]
38. A urokinase receptor mRNA binding protein-mRNA interaction regulates receptor expression and function in human pleural mesothelioma cells.
Shetty S; Idell S
Arch Biochem Biophys; 1998 Aug; 356(2):265-79. PubMed ID: 9705217
[TBL] [Abstract][Full Text] [Related]
39. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect.
Resnati M; Guttinger M; Valcamonica S; Sidenius N; Blasi F; Fazioli F
EMBO J; 1996 Apr; 15(7):1572-82. PubMed ID: 8612581
[TBL] [Abstract][Full Text] [Related]
40. Differential expression of a truncated form of the urokinase-type plasminogen-activator receptor in normal and tumor thyroid cells.
Ragno P; Montuori N; Covelli B; Hoyer-Hansen G; Rossi G
Cancer Res; 1998 Mar; 58(6):1315-9. PubMed ID: 9515821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
